Chrissy Teigen in Esquire, September 2014.
Chris does great work. Would be really interesting to see models actually do lawn work? Thought it'd make for a great series.Ā

@theartofmadeline
Mike Driver

JBB: An Artblog!
Claire Keane
ojovivo
PUT YOUR BEARD IN MY MOUTH

pixel skylines
will byers stan first human second

blake kathryn
Aqua Utopiaļ½ęµ·ć®åŗć§čØę¶ćē“”ć

Kiana Khansmith

#extradirty
Cosmic Funnies
d e v o n
I'd rather be in outer space šø
h
macklin celebrini has autism
AnasAbdin
Not today Justin
seen from United States

seen from United States

seen from United Kingdom
seen from Singapore
seen from Belarus
seen from Austria
seen from Venezuela
seen from Vietnam
seen from Chile

seen from Uruguay

seen from Uruguay

seen from Uruguay

seen from United States

seen from Türkiye
seen from United States

seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
@piercecrosby123
Chrissy Teigen in Esquire, September 2014.
Chris does great work. Would be really interesting to see models actually do lawn work? Thought it'd make for a great series.Ā

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch ⢠No registration required ⢠HD streaming
By Phil Pearlman, Interactive Editor, Yahoo Finance
Today, we are pleased to announce the launch of Yahoo Finance Contributors - a finance-focused and socially driven network where expert contributors will regularly create and share premium original content.
We are opening up...
I am glad to hear Phil has taken the first steps into a formal content platform on tumblr. There is so much potential for this site, and led by a Stocktwits alum, I see much greater upside than downside risk.Ā
Congrats Phil and YFi team.Ā
With tips from Phizer, AbbVie lands the biggest pharma deal of the year
Orchestrated by many of the deal wizards who led Pfizerās bidding for AstraZenica, AbbVie has gained verbal confirmation from Shire to move forward on the largest non-U.S. drug merger of the year. After five sequential bids, AbbVieās $53.7 billion offer for the Dublin-based company was OK-ed Monday by the board. Led by Chief Executive Rick Gonzalez, the Chicago-based drugmaker will take the reins as long as they can provide the deal logistics at the set price.
$ABBV accretive deal. hep c soon to be on the market. $70 stock.
ā Swingman24 (@Swingman24) Jul. 14 at 01:51 PM
Offering a 50.5 percent premium to Shireās market price before takeover speculation erupted four weeks ago, the deal is now only an 12 percent premium to Shireās closing price on Tuesday. AbbVie proposes to pay $44.71 in cash per share, and swap each of the remaining Shire share with 0.896 of an AbbVie share.
$ABBV getting destroyed. Overpaying for $shpg. $53 billion is way too much. Max pain coming
ā Ari Gold (@AriGold) Jul. 14 at 08:54 AM
// <![CDATA[ (function(a){var b="embedly-platform",c="script";if(!a.getElementById(b)){var d=a.createElement(c);d.id=b;d.async=true;d.src=("https:"===document.location.protocol?"https":"http")+"://cdn.embedly.com/widgets/platform.js";var e=document.getElementsByTagName(c)[0];e.parentNode.insertBefore(d,e)}})(document); // ]]>
$ABBV overpaying for $SHPG. This will not end good for Abbvie as debt load is simply astronomical on future revenues.
ā Ari Gold (@AriGold) Jul. 14 at 09:11 AM
// <![CDATA[ (function(a){var b="embedly-platform",c="script";if(!a.getElementById(b)){var d=a.createElement(c);d.id=b;d.async=true;d.src=("https:"===document.location.protocol?"https":"http")+"://cdn.embedly.com/widgets/platform.js";var e=document.getElementsByTagName(c)[0];e.parentNode.insertBefore(d,e)}})(document); // ]]>
It is hard to believe the company isnāt overpaying for the freedom to move its tax domicile, but as an analyst from British banking group Berenberg commented, āThe company has to be of a certain size, because around 20 percent of the shareholders post-deal must be shareholders in the target company.ā This ruled out quite a few of the options AbbVie could have been considering, and with quite a few companies already snapped up in the first half of the year, Shire looked like an increasingly eventual endgame.
On the value front, according to an analyst from Bank of America Merrill Lynch, pending completion, the deal will create $38 dollars per share in additional value to a combined company, which suggests AbbVie will be keeping upwards of 20 percent of that deal value to itself, discounting the purchase price significantly, and staying a lot of the complaining over the hefty premium.
Going farther than just adopting Pfizer's deal team, AbbVie offered a 5 percent larger premium to the deal, beating out Pfizer's 45 percent premium offer for AstraZenica. The company additionally inserted āsoft bidsā to assure takeover discussion remain timeless. The latter may have been even more important than the premium, considering Pfizerās final bid deadlines expired on May 18th without any takeaways to appease shareholders. The success and failure of AbbVie and Pfizer will be an important case for future dealtalk, justifying more open-ended discussionsĀ supersedeĀ strict deadlines.
Vinod Khosla has interesting ideas, one of them was to buy Google for $300,000 bucks. Unfortunately, bureaucracy would have it, Khosla couldn't authorize the deal with his boss' back in the day.Ā
In the interview with Sergey Brin and Larry Page, a lot of what Vinod says is overlooked, as many are salivating to hear the next tech prophecy from Larry & Serg, but the old timer, who founded Khosla Ventures, has some snippets of value here and there that tell us about a few problems companies he's worked with have. Just a couple quotes I've highlighted below.Ā
"It is amazing when the business people take over [a company], how quickly they get in attempting to create revenue and lose the overall vision."
Often more than not, applying business solutions people to a conceptual vision, is like using fork to play a fiddle.Ā
"I fundamentally believe that you move from an economy of labor and capital, to an economy of ideas, and most economists havenāt caught onto this change. Ideas are a disproportionately large part of the growth of the economy."
Would be interesting to get Vinod's idea of where various countries are in their cycle, compared to various companies, i.e. IBM, Tesla, India, and Russia.Ā
"Some people are good at starting things, not finishing things."
Simple, obvious, but not lacking in value. Such an important point to make in defining the success of a company.Ā
Enjoyed the watch, really glad to hear Khosla has led the $10 million round for Plastiq, which is a pretty awesome, comprehensive payments service.